Quinn

Quinn launched with a focused MVP targeting a single bottleneck in drug discovery: target identification. Rather than building a comprehensive platform covering the entire development pipeline, they concentrated on delivering defensible predictions where months of traditional work could compress into days. They deliberately excluded features like regulatory compliance tracking, manufacturing optimization, and commercial forecasting—areas they could add later once they proved core value. This narrow scope enabled rapid shipping; their first customers accessed working predictions within weeks of onboarding. The execution approach created immediate pressure to validate: if their AI couldn't demonstrably accelerate target discovery, the entire premise failed quickly and visibly. Early signals validated the bet. Pharma researchers began using Quinn's outputs to prioritize wet-lab experiments, and several customers expanded to additional discovery phases within months. This expansion demand—rather than feature requests for adjacent tools—signaled they'd solved a genuine pain point. The constraint of shipping narrow but deep became their competitive moat, forcing them to excel at one critical decision rather than mediocre at many.